Charles River narrows FY25 EPS view to $10.10-$10.30 from $9.90-$10.30

Consensus $10.19. Narrows FY25 revenue view to down 0.5%-1.5% from down 0.5%-2.5%. “In this environment, we believe it is critical to remain intently focused on our strategy to further differentiate ourselves from the competition through our science and our innovative solutions, implement additional initiatives to unlock value, and gain additional share of our clients’ drug development and manufacturing programs. This focus on our strategy and our science positions us extremely well to lead the industry through advances in drug development,” Foster concluded.